Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost‐effectiveness analysis

200784 citationsJournal Articlebronze Open Access

Authors

Gilaad G. Kaplan · Massachusetts General Hospital

Abstract

After a Crohn's patient has lost response to 5 mg/kg of infliximab, dose escalation will yield more quality-adjusted life-year compared with switching to adaliumamb; however, the cost was considerable.

Topics & Keywords

Inflammatory Bowel Disease Microscopic Colitis Biosimilars and Bioanalytical Methods

Publication Details

Published in: Alimentary Pharmacology & Therapeutics

Volume 26, Issue 11-12, pp. 1509-1520

DOI: 10.1111/j.1365-2036.2007.03548.x

Field-Weighted Citation Impact: 6.16

Command Palette

Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost‐effectiveness analysis

Authors

Abstract

Topics & Keywords

Publication Details